How to Reconstitute Retatrutide: Step-by-Step Visual Guide
A research-focused reconstitution guide for lyophilized retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, covering 5–10 mg vial sizes with research dose range examples.
Materials Needed
Required materials: lyophilized retatrutide vial (commonly 5 mg or 10 mg), bacteriostatic water vial (30 mL), U-100 insulin syringes (1 mL, 29–31 gauge), alcohol prep pads, exam gloves, and a sharps container. Retatrutide (LY3437943) is a triple-receptor agonist (GIP, GLP-1, glucagon) currently in Phase III clinical trials. It is not FDA-approved. Research use requires appropriate institutional oversight.
Calculating BAC Water Volume
For a 10 mg vial targeting 2 mg/mL: 10 mg ÷ 2 mg/mL = 5 mL BAC water. At 2 mg/mL, each 100 units on the syringe delivers 2 mg. Retatrutide research doses typically range from 0.5 mg to 12 mg in clinical protocols.
For lower concentration: 10 mg in 10 mL = 1 mg/mL; 1 mg dose = 100 units (1 mL) on the syringe.
Reconstitution Steps
Step 1 — Swab both vial stoppers with alcohol pads. Allow 30 seconds to air-dry.
Step 2 — Draw the calculated BAC water volume. For 5 mL with a 1 mL syringe, perform 5 separate draws.
Step 3 — Inject BAC water slowly along the inner wall of the retatrutide vial. Aim the needle tip at the inner glass surface to avoid disrupting the lyophilized powder cake.
Step 4 — Gently swirl in slow circular motions. Do not shake. Solution should become clear and colorless within 1–2 minutes.
Step 5 — Visually inspect for clarity. Discard if cloudy, particulate, or discolored.
Calculating Units on Syringe per Dose
Using 10 mg in 10 mL (1 mg/mL):
0.5 mg dose: 0.5 mg ÷ 1 mg/mL = 0.5 mL = 50 units.
2 mg dose: 2 mg ÷ 1 mg/mL = 2 mL = 200 units (two 1 mL syringe fills).
4 mg dose: 4 mL = four 1 mL syringe fills.
Storage After Reconstitution
Store at 2–8°C. Stability in BAC water is approximately 4–6 weeks under refrigeration. Lyophilized powder, stored cold and dry, is stable for 12–24 months. Do not freeze reconstituted solution. Label each vial with date and concentration.
Safety Notes and Research Framing
Retatrutide (LY3437943) is being studied by Eli Lilly for obesity and metabolic disease. Phase II results published in 2023 demonstrated significant weight reduction vs. placebo. As of publication, it has not received FDA approval. All material described here is research-grade. This guide does not constitute medical or clinical advice.
- What concentration should retatrutide be reconstituted to?
- 1 mg/mL (10 mg in 10 mL) or 2 mg/mL (10 mg in 5 mL) are both practical. At 1 mg/mL, each 100-unit syringe fill = 1 mg, making dose calculation straightforward for sub-milligram research doses.
- Is retatrutide FDA-approved?
- No. As of May 2026, retatrutide is in Phase III clinical trials. It is not approved for human therapeutic use and is available only as a research compound.
- How long is reconstituted retatrutide stable?
- Approximately 4–6 weeks at 2–8°C in bacteriostatic water. Label the vial with the reconstitution date and store away from light.
- Why is retatrutide particularly sensitive to shaking?
- Retatrutide's triple-agonist peptide structure is more complex than single-receptor agonists. Mechanical shear from shaking can disrupt tertiary structure and reduce binding affinity. Gentle swirling only.
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM. 2023;389(6):514-526.. https://pubmed.ncbi.nlm.nih.gov/37366315/
- Coskun T et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss. Cell Metab. 2022;35(6):1070-1083.. https://pubmed.ncbi.nlm.nih.gov/36351459/
- FDA. Bacteriostatic Water for Injection USP label.. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/016831s029lbl.pdf
Was this guide helpful?